CYCLOPHARM LIMITED (CYC)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

CYC - CYCLOPHARM LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: December
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.53
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.68

17 Jul
2024

0.000

OPEN

$1.68

0.000

HIGH

$1.68

5,256

LOW

$1.68

TARGET
$3.10 84.5% upside
Franking for last dividend paid out: 0%
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . EBR . EMV . EYE . FPH . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS
CYC: 1
Title FY22
Actual
FY23
Actual
FY24
Forecast
FY25
Forecast
EPS (cps) xxx - 5.1 - 7.5 xxx
DPS (cps) xxx 0.0 1.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.6% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

0.00

Estimated Dividend Growth
(Average Of Past Three Years)

 %

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 01/09 - ex-div 0.5c (franking 0%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx-5.1
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx27.1 M
Book Value Per Share xxxxxxxxxxxxxxx34.3
Net Operating Cash Flow xxxxxxxxxxxxxxx-7.2 M
Net Profit Margin xxxxxxxxxxxxxxx-17.32 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx-13.67 %
Return on Invested Capital xxxxxxxxxxxxxxx-12.22 %
Return on Assets xxxxxxxxxxxxxxx-9.85 %
Return on Equity xxxxxxxxxxxxxxx-13.67 %
Return on Total Capital xxxxxxxxxxxxxxx-22.97 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-8.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx4 M
Total Debt xxxxxxxxxxxxxxx4 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx12 M
Price To Book Value xxxxxxxxxxxxxxx5.62

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx0.5 M
Capex % of Sales xxxxxxxxxxxxxxx1.98 %
Cost of Goods Sold xxxxxxxxxxxxxxx23 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx13 M
Research & Development xxxxxxxxxxxxxxx4 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

04/07/2024

1

Buy

$3.10

84.52%

Bell Potter forecasts Cyclopharm will have cash on hand of around $30m post the recent $24m capital raising and the continued commercialisation of Technegas, its proprietary lung imaging agent, in the US market.

The company has received positive feedback from the FDA, which the analyst believes opens the way for potential market approval by early 2025.

The broker adjusts EPS forecasts by 8% in FY24 and -35% in FY25, with a downward revision in the target price to $3.10 from $3.40.

Buy rating unchanged.

FORECAST
Bell Potter forecasts a full year FY24 dividend of 1.00 cents and EPS of minus -7.50 cents.
Bell Potter forecasts a full year FY25 dividend of 1.00 cents and EPS of 0.10 cents.

CYC STOCK CHART